Cloud-native healthcare technology company SOPHiA GENETICS (NASDAQ:SOPH) on Tuesday announced an expanded multi-year collaboration with AstraZeneca (LSE/STO/NASDAQ:AZN) to enhance the use of artificial intelligence in improving outcomes for certain types of breast cancer.

Leveraging SOPHiA GENETICS's multimodal AI Factories, the initiative aims to generate real-world evidence on the efficacy, value, and impact of targeted therapies.

The partnership includes the potential development of a bespoke AI-powered predictive model to optimise treatment strategies for breast cancer patients. AstraZeneca will apply the AI Factories' capabilities to analyse genomic, imaging, and clinical data, providing insights to refine patient prognosis and treatment response.

The companies will also focus on real-world evidence generation in Europe and North America to identify key drivers of treatment success, address knowledge gaps, and strengthen clinical decision-making. This initiative aligns with AstraZeneca's AI strategy, which emphasises integrating multimodal datasets to gain a holistic understanding of disease biology and biomarkers.